TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7 th Framework Programme.

News & Events

 

TINN European Survey on the Use of Antibiotics in NICUs

The survey results are now available and the published article has been published.

Please click here to consult it.

 

MANY THANKS to all the Neonatal Intensive Care Units that dedicated their time to partipate in the TINN2 survey.

 

Consortium final meeting on 8th October 2015, in Paris, France

The official event of the TINN2 FP7 European Research Project was organised by Inserm-Transfert on 8th October 2015 in Paris (France).

This meeting gathered together all TINN2 partners for presenting and discussing the latest progresses within TINN2 activities, a project on preclinical studies and paediatric investigation plans for children, under the coordination of the French National Institute of Health and Medical Research (Inserm).

European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom 31st to 4th April 2012

 

TINN2 Project was presented on Poster at the ECCMID congress in London, United Kingdom.

Brochure PDF :

Erasmus 

Erasmus MC is the largest university medical centre in the Netherlands, and has with its Sophia Children’s Hospital the oldest and largest paediatric hospital in the Netherlands. The Department of Paediatrics (Prof. J van den Anker) has a world-renowned expertise in developmental and neonatal pharmacology. Furthermore, the intense collaboration between the Division of Neonatology (Prof. J van Goudoever) and the Department of Paediatric Surgery (Prof. D Tibboel) guarantees an easy access to a large population of neonates to be included in the proposed investigations. Finally, the Sophia Children’s Hospital (Dr. M de Hoog) has a leading role in the Dutch Knowledge Center for Paediatric Pharmacology and the Dutch Medicines for Children Research Network (Prof. J van den Anker) allowing an optimal situation for both enrolment of study participants and distribution of knowledge resulting from the proposed studies.

 

The Department of Paediatrics has been involved in many investigational studies in preterm and term neonates (Prs Tibboel and van den Anker) have participated in several large international multi-centre studies. The group has not only extensive experience in conducting these trials but also has specific knowledge in the area of developmental and neonatal pharmacology, PK/PD modelling, pharmacogenetics and outcome research. All these aspects will be of use for the proposed studies.

 

Professor John van den Anker is a neonatal and paediatric clinical pharmacologist with extensive experience in all aspects of neonatal and paediatric clinical trials. He is currently the President of the European Society for Developmental, Perinatal and Paediatric Pharmacology. In addition he is member of the editorial board of the top clinical pharmacology journals such as Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics. He has published over 130 peer reviewed papers and over 40 chapters in books.

 

Back to the list of institutions